https://www.selleckchem.com/pr....oducts/rgd-peptide-g
nitive performance and had 56% higher odds of caregiver distress (OR = 1.56; 95% CI 1.43 to 1.71). In our cohort of non-cancer patients dying in the community, pain, shortness of breath, impaired cognitive function and caregiver distress are important symptoms to manage near the end of life even in non-institutional settings. In our cohort of non-cancer patients dying in the community, pain, shortness of breath, impaired cognitive function and caregiver distress are important symptoms to manage near the end of life even in n